O-3,4,5-trifluorophenyl carbonochloridothioate Cas:959586-39-1

We are O-3,4,5-trifluorophenyl carbonochloridothioate CAS:959586-39-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

O-3,4,5-trifluorophenyl carbonochloridothioate

Chemical Name:O-3,4,5-trifluorophenyl carbonochloridothioate
Synonyms:O-3,4,5-trifluorophenyl carbonochloridothioate
Physical and Chemical Properties:
Density 1.590±0.06 g/cm3(
Boiling Point 212.4±35.0 °C
Molecular Formula C7H2ClF3OS
Molecular Weight 226.6033896
Appearance:Orange-red liquid or solid
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Use:Intermediate of Organic synthesis.

Market News: Sales for Tafinlar and Mekinist, the MEK inhibitor it was approved with, hit $672 million in 2016. Fast forward to 2020 and the duo generated $1.5 billion in revenue. 1,1,1,2,2,3-hexafluoropropane manufacturer.Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. apraclonidine hydrochloride supplier And finally, CHMP also concluded its investigation into bluebird bio’s Zynteglo, finding no evidence that it causes a blood cancer known as acute myeloid leukemia. O-isopropyl ethylthiocarbamate producer

Related Products
Product Name
3-Hydroxy-N-methyl-3-phenyl-propylamine Cas:42142-52-9 View Details
INOSITOL Cas:87-89-8 View Details
4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide View Details
dpac-mpm, 2dpac-mpm Cas:2019165-20-7 manufacturer 2′-Deoxycytidine Cas:207121-53-7 manufacturer ethyl butylacetylaminopropionate Cas:52304-36-6 manufacturer 1-Methylhexahydroazepin-4-one Hydrochloride Cas:19869-42-2 manufacturer 5-Bromo-2-methoxy-4-methyl-3-nitropyridine manufacturer